SK18693A3 - Improved vaccine compositions - Google Patents

Improved vaccine compositions Download PDF

Info

Publication number
SK18693A3
SK18693A3 SK18693A SK18693A SK18693A3 SK 18693 A3 SK18693 A3 SK 18693A3 SK 18693 A SK18693 A SK 18693A SK 18693 A SK18693 A SK 18693A SK 18693 A3 SK18693 A3 SK 18693A3
Authority
SK
Slovakia
Prior art keywords
vaccine
polysaccharide
adjuvant
amino acid
group
Prior art date
Application number
SK18693A
Other languages
English (en)
Slovak (sk)
Inventor
Christopher L Penney
Francis Michon
Harold J Jennings
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of SK18693A3 publication Critical patent/SK18693A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
SK18693A 1990-09-17 1991-09-12 Improved vaccine compositions SK18693A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58337290A 1990-09-17 1990-09-17
PCT/CA1991/000326 WO1992004915A1 (en) 1990-09-17 1991-09-12 Improved vaccine compositions

Publications (1)

Publication Number Publication Date
SK18693A3 true SK18693A3 (en) 1993-08-11

Family

ID=24332852

Family Applications (1)

Application Number Title Priority Date Filing Date
SK18693A SK18693A3 (en) 1990-09-17 1991-09-12 Improved vaccine compositions

Country Status (28)

Country Link
US (1) US5773007A (hu)
EP (1) EP0549617B1 (hu)
JP (1) JPH06500772A (hu)
CN (1) CN1060408A (hu)
AT (1) ATE135918T1 (hu)
AU (1) AU8441991A (hu)
BR (1) BR9106853A (hu)
CA (1) CA2090673A1 (hu)
CS (1) CS283991A3 (hu)
CZ (1) CZ42993A3 (hu)
DE (1) DE69118389T2 (hu)
DK (1) DK0549617T3 (hu)
ES (1) ES2084827T3 (hu)
FI (1) FI931169A (hu)
GR (1) GR3020117T3 (hu)
HR (1) HRP920874A2 (hu)
HU (1) HUT64237A (hu)
IE (1) IE913261A1 (hu)
IL (1) IL99403A0 (hu)
IS (1) IS3753A7 (hu)
MX (1) MX9101077A (hu)
NO (1) NO930938D0 (hu)
NZ (1) NZ239643A (hu)
OA (1) OA09776A (hu)
SK (1) SK18693A3 (hu)
WO (1) WO1992004915A1 (hu)
YU (1) YU153291A (hu)
ZA (1) ZA917356B (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US6007819A (en) * 1995-10-17 1999-12-28 Dovetail Technologies, Inc. Methods of inducing immunity using low molecular weight immune stimulants
HUP9901039A2 (hu) * 1996-02-01 1999-07-28 North American Vaccine, Inc. Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU754256C (en) 1997-12-23 2004-05-20 Pfizer Ireland Pharmaceuticals Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
AU767047B2 (en) * 1998-07-20 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Vaccines against (escherichia coli) O157 infection
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
HU228499B1 (en) * 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
RO122761B1 (ro) * 2001-01-23 2010-01-29 Aventis Pasteur Vaccin multivalent antimeningococic conţinând polizaharid-proteină
US20030035806A1 (en) * 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
AU2004281630A1 (en) * 2003-08-06 2005-04-28 Bio-Manguinhos/Fiocruz Process for preparing polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) * 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SG175092A1 (en) * 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
RU2531234C2 (ru) * 2009-06-22 2014-10-20 ВАЙЕТ ЭлЭлСи КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus
TWI469789B (zh) 2009-06-22 2015-01-21 Wyeth Llc 金黃色葡萄球菌抗原之免疫原性組合物
JP2015528456A (ja) * 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
CN102839159B (zh) * 2012-09-07 2014-03-19 江苏康淮生物科技有限公司 一种CoxA16病毒株和人用CoxA16灭活疫苗
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
EA039427B1 (ru) * 2016-08-05 2022-01-26 Санофи Пастер Инк. Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция
DK3678654T3 (da) 2017-09-07 2024-09-02 Merck Sharp & Dohme Llc Pneumokokpolysaccharider og anvendelse deraf i immunogene polysaccharid-bærerprotein-konjugater
IL304977A (en) 2018-02-05 2023-10-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
KR20190121713A (ko) 2018-04-18 2019-10-28 에스케이바이오사이언스(주) 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138773A (en) * 1979-04-18 1983-01-04 George Wojcik Synthetic adjuvants for stimulation of antigenic responses
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
EP0064366A1 (en) * 1981-04-29 1982-11-10 Beecham Group Plc Pharmaceutical compositions
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ATE60999T1 (de) * 1986-12-19 1991-03-15 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
CA1329124C (en) * 1987-02-02 1994-05-03 Jerald C. Sadoff Conjugate malaria vaccine
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
ES2070312T5 (es) * 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.

Also Published As

Publication number Publication date
AU8441991A (en) 1992-04-15
GR3020117T3 (en) 1996-08-31
OA09776A (en) 1993-11-30
IL99403A0 (en) 1992-08-18
NO930938L (no) 1993-03-16
US5773007A (en) 1998-06-30
DK0549617T3 (da) 1996-04-22
ATE135918T1 (de) 1996-04-15
DE69118389T2 (de) 1996-08-29
CS283991A3 (en) 1992-04-15
WO1992004915A1 (en) 1992-04-02
ES2084827T3 (es) 1996-05-16
FI931169A0 (fi) 1993-03-16
DE69118389D1 (de) 1996-05-02
JPH06500772A (ja) 1994-01-27
HRP920874A2 (en) 1996-04-30
MX9101077A (es) 1992-05-04
ZA917356B (en) 1992-09-30
FI931169A (fi) 1993-04-22
IS3753A7 (is) 1992-03-18
CN1060408A (zh) 1992-04-22
CZ42993A3 (en) 1994-04-13
EP0549617B1 (en) 1996-03-27
EP0549617A1 (en) 1993-07-07
HU9300746D0 (en) 1993-06-28
NZ239643A (en) 1996-05-28
IE913261A1 (en) 1992-02-25
BR9106853A (pt) 1993-08-17
CA2090673A1 (en) 1992-03-18
YU153291A (sh) 1994-06-24
HUT64237A (en) 1993-12-28
NO930938D0 (no) 1993-03-16

Similar Documents

Publication Publication Date Title
US5773007A (en) Vaccine compositions
EP0939647B2 (en) Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
US5425946A (en) Vaccines against group C Neisseria meningitidis
JP4509554B2 (ja) アルミニウムアジュバントおよびヒスチジンを含むワクチン
KR100593466B1 (ko) 다당류-펩타이드접합체
RU2105568C1 (ru) Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
CA2142981C (en) Vaccines against group c neisseria meningitidis
US6350449B1 (en) Antibodies to meningococcal polysaccharide conjugate vaccines
CA1276552C (en) Conjugate vaccine against infections by gram-negative bacteria, method for its preparation and use
US20140378669A1 (en) Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
JPH10504524A (ja) 合成ワクチンの開発に好適な免疫学的構築物において担体として使用されるペプチド類
US8926986B2 (en) Use of saccharides cross-reactive with Bacillus anthracis spore glycoprotein as a vaccine against anthrax
SVENSON et al. Protection against Mouse Typhoid by Artificial Sa/mone//a Vaccines